 |
|
Potential therapy for congenital muscular dystrophy
December 30, 2008Reno, Nevada - Current research suggests laminin, a protein that helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy. The related report by Rooney et al, "Laminin-111 restores regenerative capacity in a mouse model for alpha 7 integrin congenital myopathy," appears in the January 2009 issue of The American Journal of Pathology.
Muscular dystrophy is a group of inherited genetic diseases that cause progressive muscle weakness. In one type of muscular dystrophy, patients with mutations in the adhesion molecule alpha 7 integrin experience delayed developmental milestones and impaired mobility. There is currently no treatment or cure for alpha 7 integrin congenital myopathy.
Interactions of alpha 7 integrin with laminin, an extracellular protein found surrounding muscle fibers, promote muscle cell health and survival. Alpha 7 integrin has also been implicated in muscle repair. To determine if alpha 7 integrin is critical for muscle repair, researchers led by Dr. Dean Burkin at The University of Nevada School of Medicine examined the response to muscle damage in alpha 7 integrin-deficient mice. They found that alpha 7 integrin-deficient muscle exhibited defective muscular regeneration. Injection of laminin-111, however, restored muscle repair and regeneration.
The data from Rooney et al "indicate a critical role for the alpha7beta1 integrin and laminin in muscle repair and suggest direct muscle injections of laminin may serve as an exciting novel therapy for patients with alpha 7 integrin congenital myopathy and other muscle diseases." Dr. Burkin's group is "currently investigating the potential of this technology to treat Duchenne and other forms of muscular dystrophy. This work opens a whole new modality in therapeutics, of injecting extracellular matrix proteins to treat genetic diseases."
American Journal of Pathology
The data from Rooney et al "indicate a critical role for the alpha7beta1 integrin and laminin in muscle repair and suggest direct muscle injections of laminin may serve as an exciting novel therapy for patients with alpha 7 integrin congenital myopathy and other muscle diseases." Dr. Burkin's group is "currently investigating the potential of this technology to treat Duchenne and other forms of muscular dystrophy. This work opens a whole new modality in therapeutics, of injecting extracellular matrix proteins to treat genetic diseases."
American Journal of Pathology
Sticky protein helps reinforce fragile muscle membranes
A new study by scientists at the University of Iowa shows why muscle membranes don't rupture when healthy people exercise.
More Congenital Muscular Dystrophy Current Events and Congenital Muscular Dystrophy News Articles
 |
Congenital Muscular Dystrophies by Yukio Fukuyama (Editor), Makiko Osawa (Editor), Kayoko Saito (Editor) Hardbound. Edited by Yukio Fukuyama, who can boast a lifelong dedication to pioneering research in congenital muscular dystrophy, this volume will bring fresh impetus to new areas, and areas of research neglected in the preceding 50 years. The recognition and delineation of Fukuyama type congenital muscular dystrophy (FCMD) as a distinct clinico-genetic entity, dating back to 1960, brought about a revolutionary turn in the approach to CMD research. Knowledge of FCMD was gradually disseminated from Japan to the rest of the world, triggering an explosion of interest, and thereby facilitating a comparative study of experiences between different institutions worldwide, which led to the re-evaluation of previously overlooked related syndromes. Thus, recent progress in CMD research has... |
|
Human Laminin alfa 1 and alfa 2 Chains: Primary structures, tissue distribution and characterization of alfa 2 chain mutation in congenital muscular dystrophy by Marja Nissinen (Author) | |
|
Muscular Dystrophy Sourcebook: Basic Consumer Health Information About Congenital, Childhood-Onset, and Adult-Onset Forms of Muscular Dystrophy, Such as ... Becker, Emery-Drei (Health Reference Series) by Joyce Brennfleck Shannon (Author), Joyce Brennfleck Shannon (Editor) | |
 |
The Muscular Dystrophies by Alan E. H. Emery (Editor) The muscular dystrophies are an important group of inherited disorders. They are characterized by muscle wasting and weakness, but vary considerably in their clinical manifestations and severity. This text reviews our understanding of the most important of these disorders. In many instances, the genes and protein products responsible for the dystrophies have been identified and it is now possible to establish a precise diagnosis, detect preclinical cases, identify carriers and offer prenatal dianostic testing. The book goes on to describe the opportunities for management of the symptoms through respiratory care, physiotherapy and surgical correction of contracture, and examines the potential, in the future, for effective treatment utilizing the new techniques of gene and cell therapy.... |
 |
Duchenne Muscular Dystrophy by Alan Emery (Author), Francesco Muntoni (Author) Univ. of Edinburgh, UK. Provides an update on research and new theories concerning Duchenne muscular dystrophy. Describes screening, prenatal diagnosis, genetic counseling, and management. Text provides new understanding of the progression of the disease and advances in management of respiratory and cardiac symptoms. Previous edition: c1993. |
| © 2009 BrightSurf.com |